¬Æ»ò¬OºC©Ê¥¢¯v¡H
¥¢¯v¬O¤@ºØ¯e¯f¡HÁÙ¬O¥u¬O¤@­±¤ÏÀ³¨­¤ß¯e¯fªºÃè¤l¡H ºC©Ê¥¢¯v¸Ó¦p¦óªvÀø¡H ¨Ï¥Î§U¯v¾¯¬O¤@ºØ¸o´c©ÎºC©Ê¦Û±þ¶Ü? ºC©Ê¥¢¯vªº±wªÌ¤ÎÂå®v¤S¸Ó¦p¦ó¬Ý«ÝºC©Ê¥¢¯vªºÃĪ«ªvÀø¡H 
®Ú¾ÚÂå¾ÇÅv«ÂÂø»x¡A·s­^®æÄõÂå¾ÇÂø»x (New England Journal of Medicine) ³Ì·sªº½×¤å«ü¥X¡GºC©Ê¥¢¯v¤@¯ë¬O«ü¤JºÎ©Ò»Ý®É¶¡¶W¹L30¤ÀÄÁ¡A©ÎºÎ¯v®Ä²v¤p©ó85%¡A¥¢¯v®É¶¡¶W¹L¤@­Ó¤ë¡C¦ÓºC©Ê¥¢¯v³Ì¦³®Äªº¨âºØªvÀø¡A¬OÃĪ«¤Î»{ª¾¦æ¬°ªvÀø (Behavior Cognitive Therapy, BCT)¡C
¥i¨£±o¡A¿Å¶q¥¢¯v¹ï¨­¤ß¤Î¥Í¬¡¡B¤u§@ªº­«¤j¼vÅT¡A§Y¨Ï¾á¤ßÃĪ«ªººØºØ°Æ§@¥Î¤Î¨ä«áªG¡A¤´¦³³¡¥÷ºC©Ê¥¢¯v±wªÌ¿ï¾Ü¨Ï¥ÎÃĪ«ªvÀø¡C
ªvÀøºC©Ê¥¢¯vªºÃĪ«¥]¬A¡G BZD¡]benzodiazepine¡^±µ¨ü¾¹­P®Ä¾¯¡]agonist¡^¡B§Ü¼~Æ{¾¯¡B¤Î¥¿¬ãµo¤¤ªº²Õ´Ói±µ¨ü¾¹«ú§Ü¾¯¡B¿Æ¶Â¿E¯Àµ¥¡C¥Ø«eÂå¾Ç¤W¤w¸gª¾¹D¡ABZD±µ¨ü¾¹­P®Ä¾¯¦bÁYµu¤JºÎ®É¶¡¡B©µªøºÎ¯v®É¶¡¡B´î¤ÖºÎ¤¤²M¿ô¦¸¼Æ¡B¤Î¼W¥[ºÎ¯v«~½è¤è­±¡A³£¥i¹F¨ì70%¥H¤Wªº¦¨®Ä¡C»P¨ä¥L§U¯v¾¯¤ñ¸û°_¨Ó¡ABZDÃþ§U¯v¾¯ªº¯SÂI¬O¡Ð¡Ð¦w¥þ©Ê°ª¡A°Æ§@¥Î¤]¤Ö¡A®ÄªG¨Î¡F¦ý¨Ï¥Î³oÃþÃĪ«¤´»Ýª`·N´X­Ó­«ÂI¡A¨Ò¦p©]¶¡¬¡°Êªº¦w¥þ©Ê¡Ð¡Ð³o¨ÇÃĪ«¥i¯à¤Þ°_¤Ö¼Æ¯f¤Hª`·N¤O¤£¶°¤¤¡B·NÃѼҽk¡A¤×¨ä¦³¨Ç¦Ñ¤HªAÃÄ«á¡A±ß¤W°_§É¦p´Z¥i¯à¦b°g½k·í¤¤¶^­Ë¡A¬Æ¦Ü³y¦¨°©§é¡F¥t¥~¡A¦³¨Çªø®Ä«¬ªº§U¯v¾¯¤]¥i¯à¼vÅT¥Õ¤Ñªº¬¡°Ê¡A¾É­P¤u§@©Î¶}¨®¤¤µo¥Í·N¥~¡C¦¹¥~¡A¨Ï¥ÎBZDÃþ§U¯v¾¯¤]¥²¶·¦Ò¼{¡u¦¨Å}¡v¤Î¡u§ÙÂ_¯g­Ô¸s¡vªº°ÝÃD¡C
³Ì±`¨£ªº§ÙÂ_¯g­Ô¸s¨ä¹ê¬O¦b°±ÃÄ«á¡Aµo¥Í¡u¤Ï¼u©Ê¥¢¯v¡v¡A©¯¦n¤ñ¸û·s«¬ªº§U¯v¾¯¡A³o¤è­±ªº°ÝÃD¤w¸g¤j´T´î¤Ö¡C¦Ü©ó§ó¤Ö¨£ªº°Æ§@¥Î«h¥]¬A¥¢¾Ð¡Ð¡Ð¤×¨ä¬Oµu®Ä«¬ªº§U¯v¾¯¡A¤ñ¸û®e©ö¼vÅT°O¾Ðªº°Æ§@¥Î¡C¦³¨Ç¥¢¾Ðªº¯gª¬¥]¬A¡uºÎ¯v¤¤¶i­¹¡vµ¥¦æ¬°¤Wªº²§±`¡C
¨Ï¥ÎBZDÃþ§U¯v¾¯¡A¤]¶·¦Ò¼{¯f¤H¥¢¯vªº§Î¦¡¡A¦pªGÄÝ©ó¤JºÎ§xÃøªº¯f¤H¡A¥iµ¹¤©§@¥Î§Ö¡B¥b°I´ÁµuªºÃĪ«¡F¦pÄÝ©óºû«ùºÎ¯v§xÃøªº¡A¥iµ¹¤©§@¥ÎºC¡A¥b°I´Áµy±`ªºÃĪ«¡C¤@¯ë¦Ó¨¥¡A¯f¤H¨Ã¤£»Ý­n¤Ñ¤ÑªAÃÄ¡A¦]¦¹§Ú­Ì±j¯P«Øij¡A±wªÌ¥i¨Ì·Ó·í±ßªºª¬ªp½Õ¾ã¡A¾¨¥i¯à´î¶q©Î°±¥Î¡C¥Ñ©ó¥Ø«e©|µL¨¬°÷ªº¬ã¨s¥i¥H±oª¾BZDÃþÃĪ«ªø´Á¨Ï¥Îªº®ÄªG¤Î¼vÅT¡A¦]¦¹¤]«Øij¨Ï¥Î®É¡A¾¨¶q¤Å³sÄòªAÃĶW¹L35¤Ñ¡C
§Ü¼~Æ{¾¯¤@¯ë¦Ó¨¥¹ï¥¢¯vªºÀø®Ä¤ñBZDÃþÃĪ«®t¡A¦ý¹ï¬Y¨Ç¯f¤H¤´¦³«D±`¦nªº®ÄªG¡A¥¦ªº°Æ§@¥Î¥]¬A¤f°®¡B«K¯µ¡B«º¶Õ©Ê§C¦åÀ£¡B¶ÝºÎ¡B¤ß²v¤£¾ã¡BÅé­«¼W¥[µ¥¡C
¿Æ¶Â¿E¯À¡]melatonin¡^¬O¥Ñ¸£¤ºªQªGÅé¤Àªc¤@ºØ²üº¸»X¡A¤HÅ骺¿Æ¶Â¿E¯À·|ÀH24¤p®É¶g´Á©ÊÅܤơA©]¶¡¤É°ª¡B¥Õ¤Ñ¤U­°¡A©Ò¥H¿Æ¶Â¿E¯À¤S³QºÙ§@¡u¶Â·t²üº¸»X¡v¡C¦å¤¤¿Æ¶Â¿E¯À¿@«×¦b©]¶¡¤G¦Ü¤TÂI³Ì°ª¡A¬°¥Õ¤Ñªº5-10­¿¡A¦­¤W¤Ñ«G«á­°§C¡A¦Ü±ß¤W8ÂI¤S¶}©l¤Àªc¡C¥¦¤S·|ÀH¥Í²z¶g´Á¸`«ßÅܤơA·s¥Í¨à©]¶¡¿Æ¶Â¿E¯À¿@«×«D±`§C¡A¤T­Ó¤ë«á¶}©lª½½u¤W¤Éª½¨ì«C¬K´Á«e¡A·í¥¦¶}©l¤U­°®É¡A§Y±Ò°Ê¤@­Ó¤Hªº«C¬K´Á¡A¤§«á¤@¸ô¤U­°¡A¤×¨ä40·³«á¤U­°§ó§Ö¡A¦Ü¤C¡B¤K¤Q·³®É¦å¤¤¤w´ú¤£¨ì¿Æ¶Â¿E¯À¡C¿Æ¶Â¿E¯À¨Æ¹ê¤W¬O¤@ºØ¡u©]±ß°T¸¹¡v¡A¥i¥H¥[±jºÎ¯vÅX¤O¡A¦]¦¹³q±`¥Î©ó½Õ¾ã®É®t°ÝÃD¤Þ°_¤§¥¢¯v¡A¦ý¨Ï¥Î¾¯¶q¤Î¨Ï¥Î®É¶¡ÂI¡AÀ³»P±M·~Âå®v¸Ô²Ó°Q½×¡C